Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim plus Dexamethasone in Newly Diagnosed ITP
NCT05325593Phase 3Active, not recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Dec 2022
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 3 trial of romiplostim in primary immune thrombocytopenia (ITP), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Started Dec 2022; status: active, not recruiting.
02
Drugs
romiplostim
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT05325593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05325593.